Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-RSV nanobody ALX-0171

A trivalent nanobody composed of three monovalent Nb017 moieties linked with glycine-serine (GS) linkers, directed against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with potential activity against RSV infections. Upon administration via nebulization and inhalation, the anti-RSV nanobody ALX-0171 targets and binds to RSV F protein, neutralizing the virus, and preventing viral entry into host cells. RSV F protein is a small envelope glycoprotein required for cytopathic syncytia formation that results from cell-to-cell fusion.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-RSV F nanobody ALX-0171
anti-RSV protein F nanobody ALX-0171
RSV-specific nanobody ALX-0171
Code name:ALX 0171
ALX-0171
ALX0171
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search